stegram pharmaceuticals limited
stegram pharmaceuticals limited Company Information
Company Number
02434770
Next Accounts
Sep 2025
Shareholders
jane patricia margetts
dr lyn margetts
View AllGroup Structure
View All
Industry
Wholesale of pharmaceutical goods
+1Registered Address
45 nork way, banstead, SM7 1PB
Website
-stegram pharmaceuticals limited Estimated Valuation
Pomanda estimates the enterprise value of STEGRAM PHARMACEUTICALS LIMITED at £0 based on a Turnover of £0 and 0.83x industry multiple (adjusted for size and gross margin).
stegram pharmaceuticals limited Estimated Valuation
Pomanda estimates the enterprise value of STEGRAM PHARMACEUTICALS LIMITED at £2.1m based on an EBITDA of £451.2k and a 4.64x industry multiple (adjusted for size and gross margin).
stegram pharmaceuticals limited Estimated Valuation
Pomanda estimates the enterprise value of STEGRAM PHARMACEUTICALS LIMITED at £6.3m based on Net Assets of £3.4m and 1.85x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Stegram Pharmaceuticals Limited Overview
Stegram Pharmaceuticals Limited is a live company located in banstead, SM7 1PB with a Companies House number of 02434770. It operates in the manufacture of basic pharmaceutical products sector, SIC Code 21100. Founded in October 1989, it's largest shareholder is jane patricia margetts with a 25% stake. Stegram Pharmaceuticals Limited is a mature, unknown sized company, Pomanda has estimated its turnover at £0 with unknown growth in recent years.
Upgrade for unlimited company reports & a free credit check
Stegram Pharmaceuticals Limited Health Check
Pomanda's financial health check has awarded Stegram Pharmaceuticals Limited a 2 rating. We use a traffic light system to show it exceeds the industry average on 2 measures and has 0 areas for improvement. Company Health Check FAQs
2 Strong
0 Regular
0 Weak
Size
There is insufficient data available for this Key Performance Indicator!
- - Stegram Pharmaceuticals Limited
- - Industry AVG
Growth
There is insufficient data available for this Key Performance Indicator!
- Stegram Pharmaceuticals Limited
- - Industry AVG
Production
There is insufficient data available for this Key Performance Indicator!
- Stegram Pharmaceuticals Limited
- - Industry AVG
Profitability
There is insufficient data available for this Key Performance Indicator!
- Stegram Pharmaceuticals Limited
- - Industry AVG
Employees
There is insufficient data available for this Key Performance Indicator!
- - Stegram Pharmaceuticals Limited
- - Industry AVG
Pay Structure
There is insufficient data available for this Key Performance Indicator!
- Stegram Pharmaceuticals Limited
- - Industry AVG
Efficiency
There is insufficient data available for this Key Performance Indicator!
- Stegram Pharmaceuticals Limited
- - Industry AVG
Debtor Days
There is insufficient data available for this Key Performance Indicator!
- Stegram Pharmaceuticals Limited
- - Industry AVG
Creditor Days
There is insufficient data available for this Key Performance Indicator!
- Stegram Pharmaceuticals Limited
- - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- Stegram Pharmaceuticals Limited
- - Industry AVG
Cash Balance
has cash to cover current liabilities for 528 weeks, this is more cash available to meet short term requirements (10 weeks)
- - Stegram Pharmaceuticals Limited
- - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 9%, this is a lower level of debt than the average (49.8%)
- - Stegram Pharmaceuticals Limited
- - Industry AVG
STEGRAM PHARMACEUTICALS LIMITED financials
Stegram Pharmaceuticals Limited's latest turnover from December 2023 is estimated at 0 and the company has net assets of £3.4 million. According to their latest financial statements, we estimate that Stegram Pharmaceuticals Limited has no employees and maintains cash reserves of £3.4 million as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 690,603 | 559,570 | |||||||||||||
| Other Income Or Grants | |||||||||||||||
| Cost Of Sales | 102,686 | 98,126 | |||||||||||||
| Gross Profit | 587,917 | 461,444 | |||||||||||||
| Admin Expenses | 578,394 | 457,940 | |||||||||||||
| Operating Profit | 9,523 | 3,504 | |||||||||||||
| Interest Payable | |||||||||||||||
| Interest Receivable | 347 | 806 | |||||||||||||
| Pre-Tax Profit | 9,870 | 4,310 | |||||||||||||
| Tax | -2,077 | -918 | |||||||||||||
| Profit After Tax | 7,793 | 3,392 | |||||||||||||
| Dividends Paid | |||||||||||||||
| Retained Profit | 7,793 | 3,392 | |||||||||||||
| Employee Costs | |||||||||||||||
| Number Of Employees | 4 | 4 | |||||||||||||
| EBITDA* | 9,643 | 3,664 |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 360 | 480 | |||||||||||||
| Intangible Assets | |||||||||||||||
| Investments & Other | |||||||||||||||
| Debtors (Due After 1 year) | |||||||||||||||
| Total Fixed Assets | 360 | 480 | |||||||||||||
| Stock & work in progress | |||||||||||||||
| Trade Debtors | 1,181,183 | 535,946 | 51,489 | 265,403 | 13,608 | 40,969 | 4,180 | ||||||||
| Group Debtors | |||||||||||||||
| Misc Debtors | 315,927 | 326,112 | 10,466 | 96 | 28 | 2,402 | 2,349 | ||||||||
| Cash | 3,413,125 | 2,062,055 | 2,334,337 | 2,152,285 | 1,244,736 | 426,581 | 375,175 | 140,093 | 136,990 | 107,672 | 1,193,588 | 983,292 | 861,968 | 629,361 | 510,472 |
| misc current assets | |||||||||||||||
| total current assets | 3,729,052 | 3,569,350 | 2,870,283 | 2,162,751 | 1,244,736 | 426,677 | 375,203 | 142,495 | 190,828 | 373,075 | 1,207,196 | 983,292 | 861,968 | 670,330 | 514,652 |
| total assets | 3,729,052 | 3,569,350 | 2,870,283 | 2,162,751 | 1,244,736 | 426,677 | 375,203 | 142,495 | 190,828 | 373,075 | 1,207,196 | 983,292 | 861,968 | 670,690 | 515,132 |
| Bank overdraft | |||||||||||||||
| Bank loan | |||||||||||||||
| Trade Creditors | 1,219,392 | 67,382 | 63,134 | 39,484 | 9,484 | 58,129 | 357,044 | 855,026 | 711,268 | 603,432 | 533,887 | 46,560 | |||
| Group/Directors Accounts | |||||||||||||||
| other short term finances | |||||||||||||||
| hp & lease commitments | |||||||||||||||
| other current liabilities | 335,519 | 622,026 | 1,804,741 | 886,165 | 277,585 | 92,147 | 105,273 | 105,174 | 339,562 | ||||||
| total current liabilities | 335,519 | 622,026 | 1,219,392 | 1,804,741 | 953,547 | 340,719 | 131,631 | 114,757 | 163,303 | 357,044 | 855,026 | 711,268 | 603,432 | 533,887 | 386,122 |
| loans | |||||||||||||||
| hp & lease commitments | |||||||||||||||
| Accruals and Deferred Income | |||||||||||||||
| other liabilities | |||||||||||||||
| provisions | |||||||||||||||
| total long term liabilities | |||||||||||||||
| total liabilities | 335,519 | 622,026 | 1,219,392 | 1,804,741 | 953,547 | 340,719 | 131,631 | 114,757 | 163,303 | 357,044 | 855,026 | 711,268 | 603,432 | 533,887 | 386,122 |
| net assets | 3,393,533 | 2,947,324 | 1,650,891 | 358,010 | 291,189 | 85,958 | 243,572 | 27,738 | 27,525 | 16,031 | 352,170 | 272,024 | 258,536 | 136,803 | 129,010 |
| total shareholders funds | 3,393,533 | 2,947,324 | 1,650,891 | 358,010 | 291,189 | 85,958 | 243,572 | 27,738 | 27,525 | 16,031 | 352,170 | 272,024 | 258,536 | 136,803 | 129,010 |
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||||||
| Operating Profit | 9,523 | 3,504 | |||||||||||||
| Depreciation | 360 | 120 | 160 | ||||||||||||
| Amortisation | |||||||||||||||
| Tax | -2,077 | -918 | |||||||||||||
| Stock | |||||||||||||||
| Debtors | -1,191,368 | 971,349 | 525,480 | 10,466 | -96 | 68 | -2,374 | -51,436 | -211,565 | 251,795 | 13,608 | -40,969 | 36,789 | 4,180 | |
| Creditors | -1,219,392 | 1,219,392 | -67,382 | 4,248 | 23,650 | 30,000 | -48,645 | -298,915 | -497,982 | 143,758 | 107,836 | 69,545 | 487,327 | 46,560 | |
| Accruals and Deferred Income | -286,507 | 622,026 | -1,804,741 | 918,576 | 608,580 | 185,438 | -13,126 | 99 | 105,174 | -339,562 | 339,562 | ||||
| Deferred Taxes & Provisions | |||||||||||||||
| Cash flow from operations | 118,542 | 384,688 | |||||||||||||
| Investing Activities | |||||||||||||||
| capital expenditure | |||||||||||||||
| Change in Investments | |||||||||||||||
| cash flow from investments | |||||||||||||||
| Financing Activities | |||||||||||||||
| Bank loans | |||||||||||||||
| Group/Directors Accounts | |||||||||||||||
| Other Short Term Loans | |||||||||||||||
| Long term loans | |||||||||||||||
| Hire Purchase and Lease Commitments | |||||||||||||||
| other long term liabilities | |||||||||||||||
| share issue | |||||||||||||||
| interest | 347 | 806 | |||||||||||||
| cash flow from financing | 347 | 126,424 | |||||||||||||
| cash and cash equivalents | |||||||||||||||
| cash | 1,351,070 | -272,282 | 182,052 | 907,549 | 818,155 | 51,406 | 235,082 | 3,103 | 29,318 | -1,085,916 | 210,296 | 121,324 | 232,607 | 118,889 | 510,472 |
| overdraft | |||||||||||||||
| change in cash | 1,351,070 | -272,282 | 182,052 | 907,549 | 818,155 | 51,406 | 235,082 | 3,103 | 29,318 | -1,085,916 | 210,296 | 121,324 | 232,607 | 118,889 | 510,472 |
stegram pharmaceuticals limited Credit Report and Business Information
Stegram Pharmaceuticals Limited Competitor Analysis
Perform a competitor analysis for stegram pharmaceuticals limited by selecting its closest rivals, whether from the MANUFACTURING sector, other mature companies, companies in SM7 area or any other competitors across 12 key performance metrics.
stegram pharmaceuticals limited Ownership
STEGRAM PHARMACEUTICALS LIMITED group structure
Stegram Pharmaceuticals Limited has no subsidiary companies.
Ultimate parent company
STEGRAM PHARMACEUTICALS LIMITED
02434770
stegram pharmaceuticals limited directors
Stegram Pharmaceuticals Limited currently has 3 directors. The longest serving directors include Mr Peter Ellson (Oct 1991) and Mr Paul Margetts (Apr 2005).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Mr Peter Ellson | 90 years | Oct 1991 | - | Director | |
| Mr Paul Margetts | England | 50 years | Apr 2005 | - | Director |
| Ms Lyn Pugh | United Kingdom | 55 years | Sep 2005 | - | Director |
P&L
December 2023turnover
0
-100%
operating profit
451.2k
0%
gross margin
0%
0%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
December 2023net assets
3.4m
+0.15%
total assets
3.7m
+0.04%
cash
3.4m
+0.66%
net assets
Total assets minus all liabilities
stegram pharmaceuticals limited company details
company number
02434770
Type
Private limited with Share Capital
industry
46460 - Wholesale of pharmaceutical goods
21100 - Manufacture of basic pharmaceutical products
incorporation date
October 1989
age
36
incorporated
UK
ultimate parent company
accounts
Total Exemption Full
last accounts submitted
December 2023
previous names
N/A
accountant
MARDEN & CO ACCOUNTANTS LIMITED
auditor
-
address
45 nork way, banstead, SM7 1PB
Bank
-
Legal Advisor
-
stegram pharmaceuticals limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to stegram pharmaceuticals limited.
stegram pharmaceuticals limited Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for STEGRAM PHARMACEUTICALS LIMITED. This can take several minutes, an email will notify you when this has completed.
stegram pharmaceuticals limited Companies House Filings - See Documents
| date | description | view/download |
|---|
